Janssen Pharmaceutica Nv

Dart Neuroscience, (Cayman) Ltd.

Ortho-Mcneil Pharmaceutical Corp.

Elan Pharmaceuticals, Inc.

Wyeth

Janssen Pharmaceutica

Janssen Pharmaceuticals, Inc.

Kiev S Ly

Michael Anthony Letavic

Chandravadan R Shah

Brock T Shireman

Brad M Savall

Dale A Rudolph

Daniel J Pippel

Wenying Chai

Devin M Swanson

Neelakandha S Mani

Nicholas I Carruthers

Frank John Villani, Jr

Akinola Soyode-Johnson

James Patrick Edwards

Eugene D Thorsett

Wei Xiao

Laurent Gomez

John M Keith

Andrei William Konradi

Michael A Pleiss

Cheryl A Grice

Christopher Michael Semko

Dimitrios Sarantakis

Ronald L Wolin

Emily M Stocking

Kathleen C Sappey

James Breitenbucher

Robert Huerta Lemus

Jill A Jablonowski

Akinola Soyode Johnson

Troy Vickers

Hua M Zhong

Chennagiri R Pandit

John E Mills

Graeme Freestone

William Vernier

Margaret McCarrick

Curt A Dvorak

Barbara A Pio

Timothy W Lovenberg

Christopher Joseph Soares

Bryan James Branstetter

Jennifer Diane Venable

Susan Ashwell

Jianmei Wei

Anthony Frank Kreft

Haripada Khatuya

Gregory Scott Welmaker

Terence P Keenan

Christine M Tarby

Richard Apodaca

Lars Karlsson

Robin L Thurmond

Hua Zhong

Robert Warren Sullivan

Tami Jo Marrone

Annette K Kwok

Amy Lynn Allan

Lana K Young

Siquan Sun

Frank J Villani, Jr

Leslie A Gomez

Siguan Sun

Jennifer D Kreisberg

Michael Bogenstaetter

Richard L Apodaca

Kathleen C Strother

Barbara Pio

Disubstituted octahydropyrrolo[3,4-c]pyrrole compounds are described, which are useful as orexin receptor modulators. Such compounds may be useful in pharmaceutical compositions and methods for the treatment of diseased states, disorders, and conditions mediated by orexin activity, such as insomnia.

Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators

The invention provides a chemical entity of Formula (I): wherein R, R, X, Y and Z have any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods as disclosed herein, including metabolic and reaction kinetic studies; detection and imaging techniques; radioactive treatments; modulating and treating disorders mediated by PDE2 activity; treating neurological disorders, CNS disorders, dementia, neurodegenerative diseases, and trauma-dependent losses of function; treating stroke, including cognitive and motor deficits during stroke rehabilitation; facilitating neuroprotection and neurorecovery; enhancing the efficiency of cognitive and motor training, including animal skill training protocols; and treating peripheral disorders, including hematological, cardiovascular, gastroenterological, and dermatological disorders.

Substituted [1,2,4]triazolo[1,5-a]pyrimidin-7-yl compounds as PDE2 inhibitors

Disubstituted octahydropyrrolo[3,4-C]pyrroles as orexin receptor modulators

Substituted [1,2,4]triazolo[1,5-A]pyrimidin-7-yl compounds as PDE2 inhibitors

The invention provides a chemical entity of Formula (I): (I), wherein R, R, R, and R, have any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies; detection and imaging techniques; radioactive treatments; modulating and treating disorders mediated by PDE2 activity; treating neurological disorders, CNS disorders, dementia, neurodegenerative diseases, and trauma-dependent losses of function; treating stroke, including cognitive and motor deficits during stroke rehabilitation; facilitating neuroprotection and neurorecovery; enhancing the efficiency of cognitive and motor training; and treating peripheral disorders, including hematological, cardiovascular, gastroenterological, and dermatological disorders.

Substituted 5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-amine compounds as PDE2 inhibitors

The invention provides a chemical entity of Formula (I) wherein R, R, X, Y and Z have any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods as disclosed herein, including metabolic and reaction kinetic studies; detection and imaging techniques; radioactive treatments; modulating and treating disorders mediated by PDE2 activity; treating neurological disorders, CNS disorders, dementia, neurodegenerative diseases, and trauma-dependent losses of function; treating stroke, including cognitive and motor deficits during stroke rehabilitation; facilitating neuroprotection and neurorecovery; enhancing the efficiency of cognitive and motor training, including animal skill training protocols; and treating peripheral disorders, including hematological, cardiovascular, gastroenterological, and dermatological disorders. 

Certain substituted pyridyl amide compounds are histamine Hreceptor modulators useful in the treatment of histamine Hreceptor-mediated diseases.

Substituted pyridyl amide compounds as modulators of the histamine H3 receptor

Certain disubstituted 3,8-diaza-bicyclo[4.2.0]octane and 3,6-diazabicyclo[3.2.0]heptane are described, which are useful as orexin inhibitors. Such compounds may be useful in pharmaceutical compositions and methods for the treatment of diseased states, disorders, and conditions mediated by orexin activity, such as insomnia.

[object Object]

Disubstituted 3,8-diaza-bicyclo[4.2.0]octane and 3,6-diazabicyclo[3.2.0]heptane compounds are described, which are useful as orexin receptor modulators. Such compounds may be useful in pharmaceutical compositions and methods for the treatment of diseased states, disorders, and conditions mediated by orexin activity, such as insomnia.

Fused heterocyclic compounds as orexin receptor modulators

Growing community of inventors

San Diego, CA, United States of America

Kiev S Ly